Место цефалоспоринов в терапии инфекции нижних мочевыводящих путей

Abstract

Therapy of lower urinary tract infections (LUTI), such as cystitis or asymptomatic bacteriuria, commonly turns out to be a more difficult task in practice than it seems at first glance. The choice of antibacterial drugs should be made taking into account their efficacy, proven in clinical studies, tolerability, adverse events, as well as their cost and availability. Numerous results of epidemiological studies indicate a steady increase in the resistance of uropathogens to antibiotics, which, in turn, leads to an increase in the number of cases of ineffective therapy and recurrent disease forms. When choosing an antibiotic, preference should be given to drugs with a low selection risk of resistant microorganisms and collateral damage development, such as fosfomycin and nitrofurans recommended as first-line therapy drugs. According to the current federal clinical guidelines, third-generation cephalosporins are recommended for use as an alternative therapy for LUTI, including in pregnant women, in allergies, intolerance, lack of sensitivity of the pathogen according to bacteria tests or previous ineffective treatment with first-line drugs. This article presents the literature data on the efficacy of the third-generation cephalosporin use in the treatment of LUTI. KEYWORDS: cystitis, lower urinary tract infection, uropathogens, cephalosporins, cefixime, clinical recommendations. FOR CITATION: Kuzmenko A.V., Kuzmenko V.V., Gyaurgiev T.A. The place of cephalosporins in the treatment of lower urinary tract infection. Russian Medical Inquiry. 2023;7(4):212–217 (in Russ.). DOI: 10.32364/2587-6821-2023-7-4-212-217.